Article

<i>YES1</i> amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

2018-03-16

Abstract excerpt

<h4>ABSTRACT</h4> In approximately 30% of patients with EGFR -mutant lung adenocarcinomas whose disease progresses on EGFR inhibitors, the basis for acquired resistance remains unclear. We have integrated transposon mutagenesis screening in an EGFR -mutant cell line and clinical genomic sequencing in cases of acquired resistance to identify novel mechanisms of resistance to EGFR inhibitors. The most prominent c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1541d6e2-7cdc-5468-b0b2-7173a011635a
DOI: 10.1101/275974

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>YES1</i> amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomicsDOI 10.1101/275974Read

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomicsSemantic proximity Read

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.Semantic proximity Read

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.Semantic proximity Read

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitorsSemantic proximity Read

Acquired ROS1 Intragenic Rearrangements as a Resistance Mechanism in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Series.Semantic proximity Read

EZR-ROS1 rearrangement as a novel mechanism of acquired resistance to EGFR-TKIs in NSCLC: a case report and literature review.Semantic proximity Read

Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells.Semantic proximity Read

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.Semantic proximity Read

[Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].Semantic proximity Read

Integrative Genomic Analysis of Drug Resistance in MET Exon 14 Skipping Lung Cancer Using Patient-Derived Xenograft ModelsSemantic proximity Read

<i>MET</i> Exon 14 Skipping in Non-Small Cell Lung CancerSemantic proximity Read